Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Taking Steps To Simplify Combo Product Consultations

This article was originally published in The Tan Sheet

Executive Summary

The agency releases an internal assessment of how it handles inter-center consultations for combination products. As expected, there are some serious challenges to collaboration between the centers, but FDA says it is taking tangible steps to make it better.

Advertisement

Related Content

Companies Want New US FDA Council To Help Resolve Inter-Agency Combo Product Disputes
Be Careful What You Ask For With Combo Product Designation Requests
Senate Bill Aimed At Streamlining Combo Product Regulation
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Human Factors Questions Drive Rise In FDA Inter-Center Consults
Combination Products Offer Regulatory Option For Novel Switches

Topics

Advertisement
UsernamePublicRestriction

Register

PS107961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel